A detailed history of Jpmorgan Chase & CO transactions in Axogen, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,225 shares of AXGN stock, worth $258,795. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,225
Previous 16,419 11.0%
Holding current value
$258,795
Previous $132,000 0.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$5.67 - $8.06 $10,240 - $14,556
1,806 Added 11.0%
18,225 $131,000
Q1 2024

May 10, 2024

SELL
$6.63 - $10.69 $69,469 - $112,009
-10,478 Reduced 38.96%
16,419 $132,000
Q4 2023

Feb 12, 2024

SELL
$3.61 - $7.76 $3,299 - $7,092
-914 Reduced 3.29%
26,897 $183,000
Q3 2023

Nov 14, 2023

SELL
$4.68 - $9.26 $21,565 - $42,670
-4,608 Reduced 14.21%
27,811 $139,000
Q2 2023

Aug 11, 2023

BUY
$8.5 - $10.38 $3,978 - $4,857
468 Added 1.46%
32,419 $295,000
Q1 2023

May 18, 2023

BUY
$7.53 - $10.95 $233,889 - $340,117
31,061 Added 3490.0%
31,951 $301,000
Q1 2023

May 11, 2023

SELL
$7.53 - $10.95 $173,355 - $252,090
-23,022 Reduced 96.28%
890 $8,000
Q4 2022

Feb 13, 2023

BUY
$9.44 - $13.09 $15,217 - $21,101
1,612 Added 7.23%
23,912 $238,000
Q3 2022

Nov 14, 2022

BUY
$8.14 - $12.25 $3,646 - $5,488
448 Added 2.05%
22,300 $266,000
Q2 2022

Aug 11, 2022

BUY
$6.99 - $10.0 $23,577 - $33,730
3,373 Added 18.25%
21,852 $179,000
Q1 2022

May 11, 2022

BUY
$7.26 - $10.7 $24,662 - $36,347
3,397 Added 22.52%
18,479 $146,000
Q4 2021

Feb 10, 2022

SELL
$8.8 - $16.0 $77,704 - $141,280
-8,830 Reduced 36.93%
15,082 $142,000
Q3 2021

Nov 12, 2021

BUY
$15.23 - $21.72 $364,179 - $519,368
23,912 New
23,912 $378,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $600M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.